vs
Revvity（RVTY）与E.W. SCRIPPS Co（SSP）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是E.W. SCRIPPS Co的1.4倍（$772.1M vs $560.3M），Revvity净利率更高（12.7% vs -5.1%，领先17.8%），Revvity同比增速更快（5.9% vs -23.1%），Revvity自由现金流更多（$161.8M vs $31.2M），过去两年Revvity的营收复合增速更高（9.0% vs -0.1%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
E.W.斯克里普斯公司简称斯克里普斯，是美国的广播传媒企业，1878年由爱德华·威利斯·斯克里普斯与姐姐艾伦·勃朗宁·斯克里普斯创立，最初为日报连锁企业，前身是一家传媒集团，如今总部位于俄亥俄州辛辛那提市的斯克里普斯中心，企业格言为“给人光明，大众自寻前路”，品牌标识为沿用已久的灯塔。
RVTY vs SSP — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$560.3M
营收增速更快
RVTY
高出28.9%
-23.1%
净利率更高
RVTY
高出17.8%
-5.1%
自由现金流更多
RVTY
多$130.5M
$31.2M
两年增速更快
RVTY
近两年复合增速
-0.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $560.3M |
| 净利润 | $98.4M | $-28.5M |
| 毛利率 | — | — |
| 营业利润率 | 14.5% | 7.5% |
| 净利率 | 12.7% | -5.1% |
| 营收同比 | 5.9% | -23.1% |
| 净利润同比 | 3.9% | -129.9% |
| 每股收益（稀释后） | $0.86 | $-0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYSSP
| Q4 25 | $772.1M | $560.3M | ||
| Q3 25 | $698.9M | $525.9M | ||
| Q2 25 | $720.3M | $540.1M | ||
| Q1 25 | $664.8M | $524.4M | ||
| Q4 24 | $729.4M | $728.4M | ||
| Q3 24 | $684.0M | $646.3M | ||
| Q2 24 | $691.7M | $573.6M | ||
| Q1 24 | $649.9M | $561.5M |
净利润RVTYSSP
| Q4 25 | $98.4M | $-28.5M | ||
| Q3 25 | $46.7M | $-33.0M | ||
| Q2 25 | $53.9M | $-36.0M | ||
| Q1 25 | $42.2M | $-3.5M | ||
| Q4 24 | $94.6M | $95.4M | ||
| Q3 24 | $94.4M | $47.8M | ||
| Q2 24 | $55.4M | $1.4M | ||
| Q1 24 | $26.0M | $1.6M |
毛利率RVTYSSP
| Q4 25 | — | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 54.5% | — | ||
| Q1 25 | 56.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 54.6% | — |
营业利润率RVTYSSP
| Q4 25 | 14.5% | 7.5% | ||
| Q3 25 | 11.7% | 7.2% | ||
| Q2 25 | 12.6% | 14.2% | ||
| Q1 25 | 10.9% | 5.2% | ||
| Q4 24 | 16.3% | 26.3% | ||
| Q3 24 | 14.3% | 18.8% | ||
| Q2 24 | 12.4% | 9.7% | ||
| Q1 24 | 6.8% | 7.7% |
净利率RVTYSSP
| Q4 25 | 12.7% | -5.1% | ||
| Q3 25 | 6.7% | -6.3% | ||
| Q2 25 | 7.5% | -6.7% | ||
| Q1 25 | 6.4% | -0.7% | ||
| Q4 24 | 13.0% | 13.1% | ||
| Q3 24 | 13.8% | 7.4% | ||
| Q2 24 | 8.0% | 0.2% | ||
| Q1 24 | 4.0% | 0.3% |
每股收益（稀释后）RVTYSSP
| Q4 25 | $0.86 | $-0.51 | ||
| Q3 25 | $0.40 | $-0.55 | ||
| Q2 25 | $0.46 | $-0.59 | ||
| Q1 25 | $0.35 | $-0.22 | ||
| Q4 24 | $0.77 | $0.94 | ||
| Q3 24 | $0.77 | $0.37 | ||
| Q2 24 | $0.45 | $-0.15 | ||
| Q1 24 | $0.21 | $-0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $27.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $1.2B |
| 总资产 | $12.2B | $5.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RVTYSSP
| Q4 25 | $919.9M | $27.9M | ||
| Q3 25 | $931.4M | $54.7M | ||
| Q2 25 | $991.8M | $31.7M | ||
| Q1 25 | $1.1B | $24.0M | ||
| Q4 24 | $1.2B | $23.9M | ||
| Q3 24 | $1.2B | $34.6M | ||
| Q2 24 | $2.0B | $26.7M | ||
| Q1 24 | $1.7B | $30.2M |
总债务RVTYSSP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益RVTYSSP
| Q4 25 | $7.3B | $1.2B | ||
| Q3 25 | $7.4B | $1.3B | ||
| Q2 25 | $7.6B | $1.3B | ||
| Q1 25 | $7.6B | $1.3B | ||
| Q4 24 | $7.7B | $1.3B | ||
| Q3 24 | $7.9B | $1.2B | ||
| Q2 24 | $7.9B | $1.2B | ||
| Q1 24 | $7.8B | $1.2B |
总资产RVTYSSP
| Q4 25 | $12.2B | $5.0B | ||
| Q3 25 | $12.1B | $5.1B | ||
| Q2 25 | $12.4B | $5.1B | ||
| Q1 25 | $12.4B | $5.1B | ||
| Q4 24 | $12.4B | $5.2B | ||
| Q3 24 | $12.8B | $5.3B | ||
| Q2 24 | $13.4B | $5.3B | ||
| Q1 24 | $13.4B | $5.3B |
负债/权益比RVTYSSP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | $45.1M |
| 自由现金流经营现金流 - 资本支出 | $161.8M | $31.2M |
| 自由现金流率自由现金流/营收 | 21.0% | 5.6% |
| 资本支出强度资本支出/营收 | 2.6% | 2.5% |
| 现金转化率经营现金流/净利润 | 1.85× | — |
| 过去12个月自由现金流最近4个季度 | $509.4M | $6.5M |
8季度趋势，按日历期对齐
经营现金流RVTYSSP
| Q4 25 | $182.0M | $45.1M | ||
| Q3 25 | $138.5M | $21.8M | ||
| Q2 25 | $134.3M | $-10.5M | ||
| Q1 25 | $128.2M | $-3.3M | ||
| Q4 24 | $174.2M | $153.3M | ||
| Q3 24 | $147.9M | $140.6M | ||
| Q2 24 | $158.6M | $26.4M | ||
| Q1 24 | $147.6M | $45.4M |
自由现金流RVTYSSP
| Q4 25 | $161.8M | $31.2M | ||
| Q3 25 | $120.0M | $6.4M | ||
| Q2 25 | $115.5M | $-22.7M | ||
| Q1 25 | $112.2M | $-8.4M | ||
| Q4 24 | $149.8M | $146.9M | ||
| Q3 24 | $125.6M | $127.4M | ||
| Q2 24 | $136.6M | $2.8M | ||
| Q1 24 | $129.7M | $23.3M |
自由现金流率RVTYSSP
| Q4 25 | 21.0% | 5.6% | ||
| Q3 25 | 17.2% | 1.2% | ||
| Q2 25 | 16.0% | -4.2% | ||
| Q1 25 | 16.9% | -1.6% | ||
| Q4 24 | 20.5% | 20.2% | ||
| Q3 24 | 18.4% | 19.7% | ||
| Q2 24 | 19.7% | 0.5% | ||
| Q1 24 | 20.0% | 4.1% |
资本支出强度RVTYSSP
| Q4 25 | 2.6% | 2.5% | ||
| Q3 25 | 2.6% | 2.9% | ||
| Q2 25 | 2.6% | 2.3% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 3.4% | 0.9% | ||
| Q3 24 | 3.3% | 2.0% | ||
| Q2 24 | 3.2% | 4.1% | ||
| Q1 24 | 2.7% | 3.9% |
现金转化率RVTYSSP
| Q4 25 | 1.85× | — | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 2.49× | — | ||
| Q1 25 | 3.03× | — | ||
| Q4 24 | 1.84× | 1.61× | ||
| Q3 24 | 1.57× | 2.94× | ||
| Q2 24 | 2.87× | 18.45× | ||
| Q1 24 | 5.67× | 27.94× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
SSP
| Local Media Segment | $355.1M | 63% |
| Scripps Networks | $199.5M | 36% |
| Political Advertising Revenue | $10.0M | 2% |
